News | July 18, 2021
Veeda Clinical Research acquires majority stake in Bioneeds
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
The first batch will be shipped to the Gamaleya Center for the quality control
According to IQVIA sales data for the 12 month period ending April 2021, the Ofev Capsules, 100 mg and 150 mg market achieved annual sales of approximately US $1.6 billion
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
Aurobindo has one of the most enduring generics ecosystems among peers
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
The company plans to aggressively invest in longer gestation period projects like innovation, biosimilars, vaccines, etc.
The company is working closely with its six manufacturing partners in India
Subscribe To Our Newsletter & Stay Updated
